CardiacSense Ltd

CardiacSense Ltd is a healthcare technology company focused on developing advanced cardiac monitoring solutions through its innovative medical watch, which continuously tracks vital heart metrics. Founded in 2009 in Israel, CardiacSense Ltd specializes in cardiac monitoring technology exemplified by its flagship product, the CardiacSense medical watch. The company, led by CEO Eldad Shemesh, has been active in securing funding with its most recent deal occurring on September 21, 2020, when it raised USD 7. 5 mn.

The firm has successfully completed a total of 14 deals. CardiacSense specializes in innovative healthcare technology, primarily through its flagship product, the CardiacSense medical watch. This advanced device continuously monitors vital cardiac metrics, including heart rate and the detection of arrhythmias such as atrial fibrillation (AF). The watch utilizes a proprietary algorithm that has demonstrated high sensitivity and specificity in clinical trials, making it comparable to traditional ECG monitoring.

The company aims to address the pressing need for constant cardiovascular monitoring, particularly for individuals suffering from hypertension and other heart-related conditions. CardiacSense markets its products across various international markets, with a focus on regions such as North America and Europe, serving a diverse clientele that includes healthcare professionals, hospitals, insurers, and patients requiring ongoing monitoring of their cardiac health. CardiacSense generates revenue through a combination of direct sales and strategic partnerships, primarily targeting healthcare providers and institutions. The company operates through a B2B model, offering its medical watch as part of comprehensive healthcare solutions for continuous patient monitoring.

Revenue transactions typically involve agreements with hospitals and healthcare systems that integrate the CardiacSense watch into their patient care protocols. This model allows for bulk purchases and long-term partnerships, facilitating expanded access to their technology. The pricing structure for the CardiacSense medical watch aligns with industry standards for medical devices, reflecting the quality and precision of the technology provided. This approach reinforces their commitment to delivering effective heart monitoring solutions while ensuring that their offerings remain accessible to a wide range of healthcare entities.

Looking forward, CardiacSense plans to leverage the USD 7. 5 mn raised in September 2020 to enhance its product offerings and expand into new markets. The company is designing new features and products for the medical watch, aiming for a release in the upcoming fiscal year. Additionally, CardiacSense is targeting expansion into additional European and North American markets to increase its customer base and enhance accessibility to its cardiac monitoring solutions.